Compare Novartis AG (NVS) vs Unity Software Inc (U) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs Unity Software Inc — how do they compare? Novartis AG trades at $143.49 (market cap $268.57B), while Unity Software Inc trades at $46.37 (market cap $20.20B). The key difference: Novartis AG is far larger — about 13.3× Unity Software Inc's market cap, and Novartis AG pays a 3.31% dividend while Unity Software Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Novartis AG for 82 Days and Unity Software Inc for 50 Days on average.
| NVS | U | |
|---|---|---|
Market Cap | $268.57B | $20.20B |
Volume | 1,532,573 | 15,432,191 |
Sector | Health | Technology |
52-Week High | $168.62 | $49.47 |
52-Week Low | $121.80 | $17.13 |
Typical Hold Time | 82 Days | 50 Days |
Enterprise Value | $309.89B | $20.08B |
Dividend Yield | 3.31% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis (NVS) trades at $143.28, up 1.77% on the day, with a neutral technical signal and mixed earnings history. The company reported strong 2025 revenue of $56.67B and a net income margin of 22.5%, supported by a recent $7.8B licensing deal with China's Abogen. However, recent clinical trial setbacks and an ongoing law firm investigation introduce uncertainty.
The outlook is balanced; solid profitability and a consensus price target of $146.00 suggest modest upside, but risks from pipeline failures and heightened M&A scrutiny warrant caution. Investor sentiment is mixed, with analysts predominantly holding a neutral stance amid evolving business developments.
Unity Software (U) trades at $45.44, up 1.09% on the day, with a bullish technical signal and strong analyst support. The stock is near its pivot point of $45, with immediate resistance at $46. Fundamentally, revenue reached $1.85B in 2025, but the company reported a net loss of -$402.77M, though losses are narrowing year-over-year. Recent news highlights momentum from Meta VR Glasses support and positive sector sentiment.
Outlook: Strong buy consensus (82% of analysts) and a $46.54 price target suggest upside, but persistent losses and high valuation ratios pose risks. Investment appeal hinges on revenue growth and path to profitability, while competitive and execution risks remain key concerns for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About Unity Software Inc
Unity Software Inc provides a software platform for creating and operating interactive, real-time 3D content. The platform can be used to create, run and monetize interactive, real-time 2D and 3D content for mobile phones, tablets, PCs, consoles, and augmented and virtual reality devices. The business is spread across the United States, Greater China, EMEA, APAC and Other Americas, of which key revenue is derived from the EMEA region. The products are used in the gaming industry, architecture and construction sector, animation industry, and designing sector.
Read more on U →
